Misses from amyotrophic lateral sclerosis hopefuls Denali Therapeutics and partners AbbVie and Calico Life Sciences mark the ...
GlobalData on MSN17d
Denali Therapeutics’ ALS therapy fails to meet primary endpoint in Phase II/III trialThe primary analysis included 186 subjects who received the therapy and 139 subjects who were given a placebo.
Zacks.com on MSN17d
Denali's ALS Study Fails to Meet Primary and Secondary EndpointsDenali Therapeutics Inc. DNLI announced disappointing top-line results from an analysis of Regimen G of the phase II/III HEALEY ALS Platform Trial on pipeline candidate DNL343. The HEALEY platform ...
Zydus received FDA approval to conduct a Phase 2b trial testing usnoflast, its oral therapy for ALS, in 210 patients.
Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the ...
Denali Therapeutics (DNLI) announced topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS Platform Trial evaluating eIF2B agonist DNL343 in the treatment of amyotrophic ...
according to topline results from the Healey ALS platform trial. Fosigotifator did not demonstrate a significant effect on disease progression, combining function and mortality measures ...
Jan. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS Platform Trial evaluating eIF2B ...
Calico, Google 's anti-aging subsidiary, has announced disappointing results from its first-ever drug trial. The experimental ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback